"10.1371_journal.pone.0053087","plos one","2013-01-08T00:00:00Z","Samir Attoub; Kholoud Arafat; An GÃ©laude; Mahmood Ahmed Al Sultan; Marc Bracke; Peter Collin; Takashi Takahashi; Thomas E Adrian; Olivier De Wever","Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates; Laboratory of Experimental Cancer Research, University Hospital, Gent, Belgium; Coastside Bio Resources, Stonington, Maine, United States of America; Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Physiology, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates","Conceived and designed the experiments: SA ODW. Performed the experiments: SA KA AG MAAS TEA. Analyzed the data: SA MB TEA ODW. Contributed reagents/materials/analysis tools: PC TT. Wrote the paper: SA ODW TEA MB TT.","Peter Collin is director, laboratory manager, employee and stock-holder of Coastside Bio Resources, a Maine, USA Corporation. Thomas Adrian and Peter Collin are co-inventors of a United States patent describing Frondoside A and other sea cucumber glycosides as putative anti-cancer agents, and may benefit financially if Frondoside A becomes a drug for human cancers. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Samir Attoub","SA",9,TRUE,2,5,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
